The company came public via a reverse merger transaction on January 28 , 2008.

Tianyin is a developer, manufacturer and supplier of patented biopharmaceutical, modernized Traditional Chinese Medicine, branded generics and other pharmaceuticals in China. The Company was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 56 modernized TCMs in the market, 23 of which are listed in the highly selective National Medicine Reimbursement List and 7 of which are listed in the Essential Drug List of China. Tianyin owns and operates two GMP manufacturing facilities and R&D platform supported by leading Chinese academic institutions. Currently Tianyin is building a 250-ton macrolide API manufacturing facility near Chengdu. Tianyin has 10 pharmaceutical product candidates pending the SFDA approval. Tianyin is equipped with an extensive nationwide distribution network throughout China with a sales force of 730 sales representatives. Tianyin is headquartered at Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees.

Reverse Merger Filing